Dallas, TX, United States of America

Anli Zhang

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Anli Zhang: Innovator in Cancer Treatment

Introduction

Anli Zhang is a prominent inventor based in Dallas, TX (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. His work focuses on utilizing advanced therapies to improve patient outcomes in oncology.

Latest Patents

Anli Zhang holds a patent for his invention titled "Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy." This patent discloses methods for treating cancers with a telomerase-mediated telomere-targeting drug, 6-thio-2'-deoxyguanosine (6-thio-dG), in combination with checkpoint inhibitors and/or radiation therapy. The methods have shown promise in leading to tumor regression through innate and adaptive immune-dependent mechanisms in syngeneic and humanized mouse cancer models. He has 1 patent to his name.

Career Highlights

Anli Zhang is affiliated with the University of Texas System, where he conducts his research and develops innovative cancer treatment methodologies. His work has garnered attention for its potential to revolutionize cancer therapies and improve patient care.

Collaborations

Anli Zhang collaborates with esteemed colleagues such as Jerry W. Shay and Yang-Xin Fu. Their combined expertise enhances the research efforts and contributes to the advancement of cancer treatment strategies.

Conclusion

Anli Zhang is a dedicated inventor whose work in cancer treatment exemplifies the potential of innovative therapies. His contributions are paving the way for new approaches in oncology, ultimately aiming to improve the lives of patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…